

NIPER SAS Nagar is developing a BiSpecific Antibody for Inflammatory conditions!!!

In one of our research program we (along with Prof. Shyam S. **Sharma**) are developing Engineered Antibody (BiSpekDAb) for the treatment of TNF- α /IL-23 mediated inflammatory diseases.

BiSpekDAb technology (presented by Sandeep) has won in the Grand Finale of National Bio Entrepreneurship Competition **#NBEC2024**, the biggest competition in the Indian Bio Innovation Calendar.

He won the Accel cash prize of 1 lakh INR for this technology.



Centre for Cellular and Molecular Platforms (C-CAMP) Post

C-CAMP Centre for Cellular and Molecular Platforms (C-CAMP)
73,380 followers
16h · Edited

🎉 The Young Guns of National Bio Entrepreneurship Competition 2024
Presenting the student team winners - all future stars of Indian biotechnology!

Congratulations to

Sandeep Sehrawat & team (Suraj H. Shinde) from National Institute of Pharmaceutical Education and Research (NIPER) ,SAS NAGAR , Mohali for winning the Accel cash prize of 1 lakh INR for their technology, BiSpekDAb™ for pulmonary inflammation (Severe Asthma)

Technology available for Co-development

For any query/information please contact us:

Prof. Abhay H. Pande
Department of Biotechnology
National Institute of Pharmaceutical Education & Research (NIPER)
Sector-67, S.A.S. Nagar, Mohali-160062, Punjab. (India)
Tel : 0172-2214682-85, Extn: 2068
E-mail: apande@niper.ac.in
IPR Cell: iprcell@niper.ac.in
Technical Cell: technicalcell@niper.ac.in

BiSpekDAb™

- ✓ is an engineered bispecific antibody
- ✓ targets both TNF- α and IL-23
- ✓ contain half-life extension partner for **improved pharmacokinetic properties**
- ✓ **attenuates pulmonary and neuroinflammation in animal models**

National Institute of Pharmaceutical and Education Research,
S.A.S Nagar, Mohali, Punjab 160062.